We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK to Acquire Sierra Oncology and Its Promising Blood Cancer Drug for $1.9 Billion
GSK to Acquire Sierra Oncology and Its Promising Blood Cancer Drug for $1.9 Billion
GlaxoSmithKline (GSK) has prevailed over six other bidders with its $1.9 billion offer to purchase Sierra Oncology, gaining the Canadian company’s promising investigational Janus kinase (JAK) inhibitor, momelotinib, for the treatment of the rare blood cancer myelofibrosis.